Title:Deciphering the Role of Peroxisome Proliferator-activated Receptor α and
Phosphodiesterase Type 5 Targets in Alzheimer's Disease
Volume: 23
Issue: 8
Author(s): Parnika M. Sose, Pravin P. Kale and Gaurav M. Doshi*
Affiliation:
- Department of Pharmacology, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle West,
Mumbai-400056, India
Keywords:
Alzheimer's disease, brain, PPAR-α, PDE5, amyloid β, preclinical studies, clinical studies.
Abstract: The most prevalent cause of dementia is Alzheimer's disease (AD). Although the global AD
rate is on a constant rise, medical research is yet to find a cure for this neurological condition. Current
available therapeutic drugs for AD treatment only provide symptomatic alleviation. Therefore, it is essential
to establish effective AD treatment strategies in addressing clinical needs. The development of
disease-modifying treatments for use in the disease's early stages and the advancement of symptomatic
drugs principally used in the disease's later stages are priorities in AD research. Given that the etiology
of AD is difficult to comprehend, using a multimodal therapy intervention that targets molecular targets
of AD-related degenerative processes is a practical strategy to change the course of AD progression.
The current review article discussed PPAR-α (Peroxisome proliferator-activated receptor-α) and
PDE5 (Phosphodiesterase type 5) targets with evidence for their preclinical and clinical importance.
Furthermore, we support the targets with AD-related processes, functions, and remedial measures. A
unique synergistic method for treating AD may involve the beneficial combinatorial targeting of these
two receptors. Furthermore, we reviewed different PDE chemical families in this research and identified
PDE5 inhibitors as one of the promising AD-related experimental and clinical disease-modifying
medications. Lastly, we suggest jointly targeting these two pathways would be more beneficial than
monotherapy in AD treatments.
